U.S. Stock Night Market Movements
BGM fell 7.24% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Stocks with High Trading Volume in the Industry
Novo Nordisk fell 0.19% in the night market. Based on recent key news:
<ol>
<li>
On March 30, the core patent for semaglutide expired in China, leading to a 50% drop in the price of Novo Nordisk's weight loss injection, causing a significant decline in stock price and a market value evaporation of over 3 trillion. Source: Sina Finance
</li>
<li>
On March 31, European stock markets evaporated €420 billion in the quarter, with Novo Nordisk's stock price plummeting about 30%, affected by industry sluggishness and competitive threats. Source: Jinshi Data
</li>
<li>
On March 31, Novo Nordisk lowered the starting dosage price of Ozempic and Wegovy in India, impacting market expectations. Source: Jinshi Data. The European stock market is sluggish, competition is intensifying, and risks are increasing.
</li>
</ol>
Pfizer fell 0.18% in the night market. Based on recent key news:
<ol>
<li>
On March 31, Pfizer's rizatriptan oral disintegrating tablets were submitted for a new indication in China for the preventive treatment of adult episodic migraines. This development may enhance market confidence in its product line, driving stock prices up. Source: Zhitong Finance
</li>
<li>
On March 31, Pfizer completed a transitional contract, leading to a reassessment of its business value in the market, boosting investor confidence and driving capital inflow. Source: Zhitong Finance
</li>
<li>
On March 31, the National Healthcare Security Administration met with Pfizer and other multinational pharmaceutical companies, further smoothing communication channels and laying the foundation for deepening cooperation. This move may enhance market expectations for Pfizer's development in the Chinese market. Source: Jinshi Data. The stability of demand for pharmaceutical stocks attracts attention.
</li>
</ol>
Eli Lilly fell 0.30% in the night market. Based on recent key news:
<ol>
<li>
On March 30, Eli Lilly reached a $2.75 billion cooperation agreement with Insilico Medicine to promote AI drug development. This collaboration enhances market confidence in Eli Lilly's position in the AI pharmaceutical field, although stock prices may fluctuate in the short term, the long-term outlook is positive. Source: Zhitong Finance
</li>
<li>
On March 31, Eli Lilly announced the acquisition of Centessa Pharmaceuticals for $7.8 billion, expanding its layout in the treatment of sleep-wake disorders. This move demonstrates Eli Lilly's proactive expansion strategy in high-growth markets. Source: Sina Finance
</li>
<li>
On March 30, the overall prosperity of the AI pharmaceutical industry is rising, and the collaboration between Eli Lilly and Insilico Medicine is seen as an industry turning point, promoting market recognition of AI technology. Source: Wall Street Insights. The prosperity of the AI pharmaceutical industry is rising, and capital inflow is evident
</li>
</ol>

BGM fell 7.24% in the night session; Novo Nordisk fell 0.19% in the night session, with a transaction volume of USD 268,200; Pfizer fell 0.18% in the night session, with a transaction volume of USD 257,900; Eli Lilly fell 0.30% in the night session, with a transaction volume of USD 134,000

U.S. stock night trading fluctuations: Night trading down 7.24%, clear capital flow, increased volatility attracts market attention!